Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15580453 | 0.80 | AR (0.32) | KDM4EMEN1LMNAGAAMAPT | |
| SCHEMBL12293745 | 0.76 | — | — | |
| SCHEMBL6805167 | 0.75 | MAOB (0.37) | KDM4EMEN1LMNAGAAMAPT | |
| SCHEMBL18704482 | 0.71 | AR (0.41) | KDM4EMEN1MAPTHPGDKMT2A | |
| SCHEMBL16473039 | 0.71 | TRPV4 (0.36) | KDM4EAR | |
| Bromide SCHEMBL2431322 | 0.70 | SNCA (0.33) | KDM4EMEN1LMNAGAAMAPT | |
| SCHEMBL8802324 | 0.67 | AKR1B1 (0.39) | KDM4ELMNAGAAHPGDHTT | |
| SCHEMBL20567319 | 0.66 | AR (0.42) | KDM4EMEN1MAPTKMT2AAR | |
| SCHEMBL20517376 | 0.65 | AR (0.39) | KDM4EAR | |
| SCHEMBL12742277 | 0.63 | CYP3A4 (0.35) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673948-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2014-03-18 | — | — | US | disclosed |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301203-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | KDM4E 1478/4885MEN1 674/4885LMNA 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.